Skip to main content

Advertisement

Table 2 Patient characteristics

From: The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

   NNRTI PI Other Total
(n = 46) [34.6%] (n = 38) [28.6%] (n = 49) [36.8%] (N = 133)
Sociodemographic factors
Patient age (in years) at diagnosis <50 36 [78.3%] 34 [89.5%] 43 [87.8%] 113 [85.0%]
≥50 10 [21.7%] 4 [10.5%] 6 [12.2%] 20 [15.0%]
Education level (college degree) No 36 [78.3%] 31 [81.6%] 41 [83.7%] 108 [81.2%]
Yes 10 [21.7%] 7 [18.4%] 8 [16.3%] 25 [18.8%]
Anamnestic factors
HIV stage according to CDC classification A + B 41 [89.1%] 24 [63.2%] 36 [73.5%] 101 [75.9%]
C (AIDS) 5 [10.9%] 14 [36.8%] 13 [26.5%] 32 [24.1%]
Three or more concomitant diseases No 37 [80.4%] 29 [76.3%] 39 [79.6%] 105 [78.9%]
Yes 9 [19.6%] 9 [23.7%] 10 [20.4%] 28 [21.1%]